comparemela.com

Latest Breaking News On - Aim immunotech inc - Page 1 : comparemela.com

AIM ImmunoTech Announces First Dose Level is Generally

Next safety cohort to begin escalated dosing soon.

United statesInvestigators at erasmus medical centerImmunotech incErasmus medical centerResponse evaluation criteriaSolid tumorsNyse aimAim immunotech incImmuno oncologyPancreatic cancer

AIM ImmunoTech to Present at the MedInvest Biotech & Pharma

Live webcast presentation on Wednesday, April 3rd at 1:35 PM ET.

New yorkUnited statesThomask equelsImmunotech incChief executive officerMedinvest biotechPharma investor conferenceNyse aimAim immunotech incImmuno oncologyBreast cancerPancreatic cancerOvarian cancerCovid 19Long covid

AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023

OCALA, Fla., March 26, 2024 (GLOBE NEWSWIRE) AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) announced today that management will.

United statesChristopher mcaleerThomask equelsImmunotech incChief executive officer thomasScientific officer christopher mcaleerTech conferenceNyse aimAim immunotech incImmuno oncologyCovid 19Long covid

AIM ImmunoTech Announces First Subject Dosed in the

Phase 1b portion of the study expected to be completed within six months.

United statesExchange commissionImmunotech incErasmus medical centerPancreato biliary surgeonResponse evaluation criteriaPrivate securities litigation reform actNyse aimAim immunotech incPancreatic cancerImmuno oncology

AIM ImmunoTech Reports Positive Topline Results from Phase

Efficacy results offer preliminary evidence that Ampligen may reduce fatigue in subjects with Post-COVID conditions Safety results show Ampligen is.

United statesChris mcaleerThomask equelsExchange commissionImmunotech incCompany phaseFatigue scoreSix minute walk testExecutive officer thomasOfficer chris mcaleerPrivate securities litigation reform actNyse aimAim immunotech incCovid 19Long covid

vimarsana © 2020. All Rights Reserved.